AOD-9604

II. What is this compound?

AOD-9604 isn't a growth hormone secretagogue or a GH analogue — it's a surgical slice of hGH itself. Structure–function work on human growth hormone had identified residues 177–191, a short C-terminal stretch linked to lipid handling, as the region worth isolating. Chemists rebuilt that stretch with a single edit: an added N-terminal tyrosine, producing a 16-amino-acid hexadecapeptide — not the 15-mer often quoted online. The sequence reads Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with a molecular weight near 1815 Da.

That one structural choice explains the entire research thesis. Peptides like sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation , CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue , and ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue work upstream, pushing the pituitary to release more GH. AOD-9604 was designed downstream of that idea — a fragment hypothesized to retain fat-metabolism activity while avoiding the GH-like rises in IGF-1 and glucose disruption reported with the intact hormone [3] PMID: 11146367 [4] PMID: 11713213 . Less hormone signaling, more targeted lipid effect — at least in theory.

The name tells you the ambition: "Advanced Obesity Drug 9604," developed as an anti-obesity drug candidate. That framing is worth holding onto whenever gray-market listings surface under HGH Fragment 177-191 branding. If you remember a single structural fact, make it this one: 16 residues, Tyr-hGH 177–191 — studied first in metabolic animal models, then in human oral and IV programs whose outcome changed the story completely.

III. How it works

Two linked actions keep surfacing in the AOD-9604 literature: more fat breakdown through lipolysis and fat oxidation, and less fat formation through suppressed lipogenesis [5] PMID: 11146367 [6] PMID: 11713213 . Push fat cells toward releasing stored energy while blocking them from rebuilding stock — that dual push-pull is the entire mechanistic pitch.

The obvious suspect was the β3-adrenergic receptor, the pathway behind catecholamine-driven lipolysis in rodents. But here's where the story gets interesting: Heffernan and colleagues ran their experiments in β3-adrenergic receptor knockout mice — animals without the receptor entirely — and the fragment still affected lipid metabolism [7] PMID: 11713213 . Whatever the peptide is doing, β3 involvement looks partial rather than exclusive, and researchers are still mapping the remaining routes.

The second differentiator matters just as much. Across the same body of work, researchers reported lipid effects without the classic GH growth signature — no meaningful impact on blood glucose or IGF-1, the complications that shadow full-length hormone use [8] PMID: 11713213 [9] PMID: 11146367 . That separation made AOD-9604 genuinely attractive as a drug candidate, and it is exactly what the human trial program would go on to test.

• Stimulation of lipolysis / fat oxidation; β3-adrenergic involvement is hypothesized but not exclusive (effect retained in β3-AR knockout mice)
  PMID 11713213PMID 11146367
• Inhibition of lipogenesis without the classic GH effects on blood glucose or IGF-1 elevation seen with intact hGH
  PMID 11713213PMID 11146367

IV. Research Findings

Start with the strongest part of the evidence file: animal models. In chronically treated obese mice, researchers reported favorable shifts in lipid metabolism — work that compared the fragment head-to-head with human GH and included β3-AR knockout animals to probe the pathway [10] PMID: 11713213 . Related metabolic studies of the synthetic lipolytic domain reached the same territory from another angle [11] PMID: 11146367 . For sixteen amino acids, that's a genuinely impressive preclinical résumé.

Human development followed, and this is where honesty pays. Multiple randomized, double-blind, placebo-controlled trials — program codes METAOD001 through 006 appear in the Stier et al. 2013 clinical synthesis — evaluated safety, tolerability, and body-weight endpoints using oral and intravenous regimens. Across those trials, AOD9604's tolerability was described as generally similar to placebo, notably free of the adverse metabolic signature classically associated with intact hGH.

Efficacy is the other half of the ledger, and it did not clear the bar. Earlier short studies were sometimes described as directionally interesting for weight change, but the larger, longer Phase IIb OPTIONS-type programs found no statistically significant weight loss versus placebo at the oral doses tested — and Metabolic Pharmaceuticals halted development around 2007. Any complete account has to carry all three findings together: real preclinical signals, documented human exposure, and a pivotal trial that came back empty.

So why does research interest persist? Because the experiment answered cleanly. The fragment behaves metabolically as animal models predicted, yet that activity didn't translate into measurable weight change at the tested doses. Working out *why* is now the genuinely open question — and it runs straight through the dosing history below.

• fat-loss mixed (animal positive; human Phase 2 efficacy inconsistent / pivotal Phase IIb failed primary endpoint)
  PMID 11713213PMID 11146367
• metabolic-health preclinical plus human safety-focused Phase 1–2 programs
  PMID 11713213PMID 11146367

V. Dosage Context Explained

Dosing language around this compound splits into three different worlds — and mixing them is how incorrect microgram claims end up glued to the wrong papers.

World one: human oral development. The Phase II program used milligram-scale daily capsules and tablets rather than microgram injections — published summaries describe Phase IIb tablet arms around 0.25, 0.5, or 1 mg/day over 24 weeks (METAOD006 / OPTIONS-era work), after earlier capsule studies explored broader oral ranges. Early IV safety studies used single doses on the order of 25–100 µg/kg in obese volunteers.

World two: animal regimens, including the Heffernan 2001 and Ng 2000 protocols — species-specific chronic schedules built to probe lipid metabolism, not plug-and-play templates for anything else [12] PMID: 11713213 [13] PMID: 11146367 .

World three lives mostly in forums: subcutaneous microgram protocols, often quoted around 250–500 mcg/day, sometimes 300–600. These are anecdotal research-community patterns — not endpoints from the oral Phase II obesity program, and not something to dress up as study-backed therapy. Every figure on this page exists as research history, which raises the obvious next question about safety.

• Administration Routes

  oral

  Range

  0.25–1 mg/day tablets (METAOD006 Phase IIb); earlier capsules up to ~1–30 mg/day in Phase IIa/IIb programs

  Human clinical development (Metabolic Pharmaceuticals): multi-trial oral program summarized in Stier et al. 2013 (JOFEM). Pivotal 24-week OPTIONS Phase IIb failed primary weight-loss endpoint; development halted ~2007. Research history only — not medical advice.

• Administration Routes

  intravenous

  Range

  single doses ~25–100 µg/kg (early Phase I/IIa safety studies)

  Early human IV single-dose safety studies in obese volunteers (METAOD001–002 program summary).

• Administration Routes

  subcutaneous

  Range

  often discussed anecdotally as ~250–500 mcg/day (sometimes cited 300–600 mcg/day)

  Anecdotal research-community protocols — NOT primary RCT endpoints from the oral Phase II program. Do not present as study-backed human therapeutic dosing.

• Administration Routes

  subcutaneous / experimental (animal)

  Range

  species- and study-specific chronic regimens in obese mouse models

  Preclinical lipid-metabolism work including Heffernan et al. (obese mice and β3-AR KO mice) [PMID: 11713213] and related metabolic studies [PMID: 11146367].

  PMID 11713213PMID 11146367

VI. Side Effects: Research Context

The cleanest human safety picture comes from the six randomized, double-blind, placebo-controlled trials summarized by Stier and colleagues in 2013: overall, AOD9604 was reported as well tolerated, with a profile described as indistinguishable from placebo — and, in the authors' framing, free of the classic adverse effects associated with intact hGH. For a compound that spent years in human trials, that's an unusually quiet ledger.

It isn't a blank check. Trial populations, durations, and routes differ from informal research use, and the anecdotal mentions — transient headache, injection-site redness — come with no incidence data behind them. Conservative research practice also flags pregnancy/breastfeeding and active malignancy as contexts to avoid, consistent with this site's compound schema.

Anyone designing actual protocols needs institutional review, legal compliance, and primary literature rather than forum folklore. What those six trials did establish is a tolerability baseline — which makes the regulatory aftermath all the more striking.

• in human RCTs: overall safety/tolerability reported similar to placebo (Stier et al. 2013 summary of six trials)
• transient headache (anecdotal research use)
• injection site redness (anecdotal subcutaneous research use)

VII. Frequently Asked Questions